# Myalgic Encephalomyelitis / Chronic Fatigue Syndrome **Prepared by:** Pedro Cheung MD **Last Updated:** May 2026 ## A Comprehensive Guide for Newly Diagnosed Patients _Based on current evidence and clinical guidelines as of May 2026_ --- ## What Is ME/CFS? Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a serious, complex, multisystem disease that causes profound disability. It is **not** simply "feeling tired." ME/CFS disrupts cellular energy production, immune function, the nervous system, and blood vessel health simultaneously. The result is a level of fatigue and functional impairment far beyond ordinary exhaustion — one that is not relieved by rest and that worsens with exertion. ME/CFS affects an estimated **2.5 million people in the United States** and over 400,000 in the United Kingdom. The majority remain undiagnosed or misdiagnosed for years. Up to 75% of patients are unable to work or attend school, and the annual economic burden runs into tens of billions of dollars in medical costs and lost productivity.[^3] For decades, ME/CFS was incorrectly dismissed as a psychological illness. That view has been thoroughly and definitively overturned. As of 2026, researchers have identified specific, measurable biological abnormalities — in immune cells, mitochondria, blood vessels, the gut microbiome, and even the 3D structure of patients' DNA — that fully explain the disease. ME/CFS is a **biomedical illness**, and it deserves the same seriousness as any other complex chronic disease.[^1] ### Key Facts at a Glance - ME/CFS often begins after a viral or bacterial infection - It affects people of all ages, sexes, and backgrounds - Severity ranges from mild impairment to permanent bedbound disability - There is significant overlap with Long COVID — research on both conditions is accelerating together[^1] - ME/CFS now has a specific ICD-10-CM diagnostic code: **G93.32** — which can help with insurance billing and disability documentation[^16] --- ## What Is Happening Inside Your Body? ME/CFS is now understood as an acquired state of **profound biological disruption** affecting multiple interconnected systems at once. The 2026 scientific consensus identifies six major areas of dysfunction.[^1] ### 1. Immune System Gone Haywire ME/CFS almost always begins after an infection — a virus, bacterium, or other pathogen. Even after the initial illness resolves, the immune system fails to return to normal. Instead, it becomes locked in a state of **chronic, low-grade inflammation**.[^5] A key discovery is the presence of **autoantibodies** — proteins the immune system mistakenly makes against the body's own receptors. These autoantibodies target receptors that control blood vessel tone and heart rate, directly causing the dizziness and heart-racing sensations many patients experience when standing.[^5] Additionally, dormant viruses such as Epstein-Barr Virus (EBV — the virus that causes mono) and HHV-6 can reactivate in the exhausted immune system, adding further inflammation and keeping the immune system perpetually overworked.[^5] The landmark NIH Deep Phenotyping Study (2024) confirmed disease-specific immune signatures in ME/CFS patients, including altered B cell phenotypes and elevated T-cell exhaustion and activation — with important differences by sex.[^17] ### 2. A Cellular Energy Crisis The mitochondria — the power plants inside every cell — are not functioning properly in ME/CFS. Specifically, a key enzyme called Pyruvate Dehydrogenase (PDH) is blocked, which prevents the cell from converting fuel into energy efficiently. Instead of clean aerobic energy, the body is forced to run on inefficient anaerobic pathways — the same system sprinters use for short bursts — even for minimal everyday activity.[^1] This produces a rapid buildup of lactic acid in muscles and tissues, causing the profound muscle pain, weakness, and the "hitting a wall" sensation that is so characteristic of ME/CFS. A January 2026 landmark study confirmed that patients have a consistent, reproducible fault in the **TRPM3 ion channel** in their immune cells — a structural defect that prevents normal calcium signaling and energy regulation. This was independently verified by multiple laboratories on different continents.[^4] A 2025 multi-omics study published in _npj Metabolic Health and Disease_ further confirmed impaired energy production in ME/CFS, demonstrating defects involving the citric acid cycle, beta-oxidation of fatty acids, and amino acid energy pathways — all of which worsened following exercise and correlated directly with symptom severity.[^22] ### 3. Gut Microbiome Dysregulation One of the most significant new findings in ME/CFS research is the role of the **gut microbiome** — the community of bacteria and other microbes living in the digestive tract. Multiple studies have now confirmed that patients with ME/CFS have a distinct and disrupted gut microbiome compared to healthy people.[^18] Key findings include: - **Lower levels of butyrate** — a beneficial fatty acid produced by healthy gut bacteria that helps regulate immune function and gut barrier integrity - **Higher levels of tryptophan and benzoate** — markers of microbial imbalance - **Elevated inflammation in MAIT cells** — immune cells that link gut health to systemic immune function - The microbiome changes appear to become more entrenched over time, suggesting that earlier intervention may produce better outcomes[^18] Researchers at Jackson Laboratory and Duke University developed an AI platform called **BioMapAI**, trained on four years of data from 249 patients, that can identify ME/CFS with **90% accuracy** by analyzing stool, blood, and routine lab tests. This is a major step toward objective diagnostic tools — and the first systems-level map linking the gut, immune system, and metabolism to specific ME/CFS symptoms.[^18] ### 4. Tiny Blood Clots Blocking Circulation Ongoing inflammation damages the lining of blood vessels throughout the body. This triggers the formation of tiny, abnormal blood clots — called **fibrin amyloid microclots** — that resist normal breakdown. These microclots physically block the tiny capillaries that deliver oxygen to muscles and the brain.[^11] This explains a crucial feature of ME/CFS called the **delayed crash**: during activity, clogged capillaries cannot supply enough oxygen. After the activity stops and blood flow returns, a surge of damaging molecules (reactive oxygen species) floods the tissues — causing the severe worsening of symptoms that typically arrives **12–48 hours later**.[^11] ### 5. Nervous System Dysregulation The autonomic nervous system — which automatically controls heart rate, blood pressure, breathing, and digestion — is significantly impaired. When a healthy person stands up, the nervous system instantly adjusts to maintain blood flow to the brain. In ME/CFS, this adjustment fails, causing blood to pool in the legs and reducing blood flow to the brain (**Preload Failure**). The result is dizziness, rapid heart rate, visual disturbances, and cognitive fog upon standing — a condition called **orthostatic intolerance**.[^2] The brain itself also shows signs of neuroinflammation, contributing to the severe cognitive difficulties, unrefreshing sleep, and sensory sensitivities many patients experience.[^1] ### 6. Changes to How Your Genes Are 'Read' — and Genetic Risk Factors Perhaps the most cutting-edge findings involve both the **3D structure of DNA** and inherited genetic risk. **Epigenetic remodeling:** ME/CFS causes changes in how DNA is folded and read inside cells — altering which genes are switched on or off. These structural changes act like a lock, keeping the body stuck in a state of illness even after the original trigger is gone. A 2025 blood test called the **EpiSwitch® test** uses this discovery to detect ME/CFS-specific chromosomal contact patterns with up to 96% overall accuracy in research settings — a promising step toward a diagnostic blood test.[^19] **Genetic signals — DecodeME:** The world's largest ME/CFS genetic study, **DecodeME**, published its landmark results in 2025. Comparing DNA from **15,579 people with ME/CFS** against nearly 260,000 controls, researchers identified **eight distinct genetic signals** linked to ME/CFS — all associated with the immune system and nervous system. Critically, none were linked to depression or anxiety, definitively separating ME/CFS genetics from psychiatric illness. Three of the strongest signals involve genes active in responding to viral or bacterial infection, and one (CA10) is associated with chronic pain. This genetic evidence validates the lived experience of patients and opens entirely new avenues for drug development.[^20] --- ## Common Symptoms and Presentations ME/CFS presents differently in different people. Severity ranges from mild (reduced activity, but able to function with modifications) to very severe (permanently bedbound, tube-fed, unable to tolerate light or sound). However, certain core symptoms are present in virtually every case.[^2] ### The Hallmark Symptom: Post-Exertional Malaise (PEM) > **Post-Exertional Malaise (PEM)** is the defining feature of ME/CFS. It is a severe worsening of all symptoms following any form of exertion — physical, cognitive, emotional, or even standing upright for too long. PEM is _not_ normal fatigue after activity. It is a true biological crash that can be triggered by activities as minor as a short conversation, a shower, or reading a few pages of a book.[^2] > > **Key features of PEM:** Onset is typically **delayed 12–48 hours** after the triggering exertion. Recovery can take days, weeks, or even months. During a crash, cognitive fog, flu-like symptoms, muscle weakness, pain, and light/sound sensitivity all intensify dramatically.[^2] ### Other Core and Common Symptoms |Symptom Area|What Patients Experience| |---|---| |**Fatigue & Energy**|Profound, new-onset fatigue lasting > 6 months; not improved by rest; unlike any prior fatigue| |**Sleep**|Unrefreshing sleep regardless of duration; insomnia; inverted sleep cycles; sleep apnea| |**Cognitive ("Brain Fog")**|Severe memory problems; difficulty concentrating; word-finding difficulties; slow thinking| |**Orthostatic Intolerance**|Dizziness, rapid heart rate, visual changes, and pre-fainting upon standing or sitting upright| |**Pain**|Widespread muscle and joint pain; headaches; sore throat; tender lymph nodes| |**Neurological / Sensory**|Light sensitivity (photophobia); sound sensitivity (hyperacusis); numbness; tingling| |**Gastrointestinal**|Nausea, bloating, irritable bowel-type symptoms, food sensitivities| |**Immune**|Flu-like feelings; recurrent sore throats; swollen lymph nodes| ### Common Overlapping Conditions ME/CFS frequently occurs alongside other conditions that must be identified and managed:[^2] - **Mast Cell Activation Syndrome (MCAS):** Causes allergic-type reactions, flushing, and GI distress - **Hypermobility / Ehlers-Danlos Syndrome (hEDS):** Joint laxity that worsens orthostatic intolerance - **Fibromyalgia:** Widespread musculoskeletal pain and heightened pain sensitivity - **Irritable Bowel Syndrome (IBS):** Gut symptoms linked to altered gut-brain signaling --- ## How Is ME/CFS Diagnosed? Historically, diagnosis took an average of **five years** and required ruling out dozens of other conditions.[^3] The modern approach is much more direct. ME/CFS can now be diagnosed **positively** — based on the presence of specific symptoms — rather than purely by elimination.[^2] ### The Four Core Diagnostic Requirements All four of the following must be present, lasting more than 6 months:[^2] |Criterion|What This Means| |---|---| |**1. Substantial Impairment**|A significant reduction in your ability to do what you could do before illness — at work, school, socially, or in daily life — accompanied by profound new-onset fatigue| |**2. Post-Exertional Malaise (PEM)**|The hallmark symptom: a worsening of all symptoms after exertion, with delayed onset| |**3. Unrefreshing Sleep**|Sleep does not restore energy, regardless of how much you get| |**4. Cognitive Impairment OR Orthostatic Intolerance**|At least one of these must be present: significant brain fog, or significant worsening of symptoms when upright| ### Baseline Tests Your Doctor Should Order Your doctor will run standard blood and urine tests to rule out other treatable causes of fatigue, such as anemia, thyroid disease, diabetes, and sleep apnea. These tests often come back **normal** in ME/CFS — which is expected and does _not_ mean you are not ill. Normal standard labs are entirely consistent with an ME/CFS diagnosis.[^2] ### ICD-10-CM Code for ME/CFS ME/CFS now has an official diagnostic code: **G93.32**. This code covers "myalgic encephalomyelitis/chronic fatigue syndrome," "chronic fatigue syndrome," and "myalgic encephalomyelitis." Ask your doctor to use this code in your medical records — it can help with insurance reimbursement and disability applications. When ME/CFS follows a COVID-19 infection, the additional code U09.9 (post-COVID condition) may also be applied.[^16] --- ## Non-Pharmacological Treatments (First-Line) Because there is currently no single cure for ME/CFS, the most important and evidence-based first step is protecting your body from further harm through careful energy management. Non-pharmacological strategies form the **absolute foundation** of ME/CFS care.[^1][^2] --- > ⚠️ **CRITICAL WARNING: Do NOT push through fatigue.** > > Graded Exercise Therapy (GET) — a formerly prescribed treatment that told patients to gradually do more exercise regardless of symptoms — has been **definitively banned** by major medical guidelines including the UK's NICE, ANZMES, and the U.S. ME/CFS Clinician Coalition. Forcing exercise on a body with ME/CFS causes severe, sometimes irreversible harm. Activity increases must always be symptom-guided, never based on fixed schedules.[^2][^8][^9][^10] --- ### 1. Pacing — The Most Important Strategy Pacing means living carefully within your body's available energy limit — called the **energy envelope**. Every person with ME/CFS has a strictly limited daily energy reserve. When you exceed it, even slightly, you trigger PEM. The goal of pacing is to stay consistently below that limit.[^2] #### The Science Behind Your Heart Rate Limit In ME/CFS, the threshold at which your body switches from efficient aerobic energy production to inefficient anaerobic energy production is **severely and pathologically lowered**. In healthy people, this "anaerobic threshold" is reached only during strenuous exercise. In ME/CFS, it can be crossed simply by standing up, having a conversation, or walking to the bathroom. When your body tips into anaerobic metabolism, lactic acid floods your tissues and sets off the biochemical cascade that causes a PEM crash — often 12–48 hours later.[^23] This is why **standard exercise formulas do not apply to you.** The familiar "220 minus your age" formula is designed for healthy hearts and will give you a target that is dangerously too high. For ME/CFS, a safer starting estimate is based on your own resting heart rate:[^23] > **Estimated safe heart rate limit = Your 7-day average resting heart rate + 15 beats per minute** For example, if your average morning resting heart rate is 70 beats per minute, stay below 85 bpm during all activity. This limit may feel frustratingly low — even slow walking can exceed it for some patients — but it is designed to protect you. If you are still experiencing PEM crashes while staying below this limit, lower your threshold until crashes stop. #### How to Measure Your Resting Heart Rate Baseline Take your resting heart rate **every morning immediately upon waking, before sitting up**. Use a chest strap monitor, a smartwatch, or even your own fingers on your wrist. Record the number for at least seven consecutive days, then calculate the average. Your morning resting heart rate also serves as a daily "check engine light": if it is 5–10 beats higher than your average, your body is signaling that it needs more rest that day, regardless of how you feel mentally.[^23] #### Setting Up Heart Rate Alerts Configure your wearable device to vibrate or sound an alert **5–10 beats below your calculated threshold** — not at the limit itself. This gives you time to sit down before you have already crossed the line. When the alarm goes off, the required action is immediate: stop what you are doing and rest until your heart rate returns to baseline. This might mean sitting on the floor in the middle of a grocery store, pausing on a staircase, or putting down a phone call. While this can feel awkward, it is the most effective way to break the push-crash cycle over time.[^23] #### Pacing Beyond Physical Activity: Cognitive and Emotional Exertion Pacing is not just for physical movement. **Cognitive tasks — reading, writing, screen time, and complex conversations — drain your energy envelope just as much as walking**, even when they do not visibly raise your heart rate. Emotional stress (anxiety, excitement, conflict) similarly consumes energy. Build mandatory rest periods around cognitive tasks. Consider limiting screen time, using audiobooks instead of reading, and keeping conversations brief on difficult days.[^2] #### Practical Pacing Tips - Plan your most important activities for your **best time of day**, and keep them brief - Break all tasks — showering, cooking, phone calls — into short segments with seated or lying-down rest in between - Rest **before** you feel tired, not after. Pre-emptive rest is far more protective than waiting until you are fatigued - Rest in a quiet, low-stimulus environment (dim light, minimal noise) - Keep a **symptom and activity diary** to identify your personal crash triggers and patterns - Remember that "doing nothing" during rest means no screens, no phone, no conversation — true sensory rest #### Heart Rate Monitors and Wearables: What to Use **Chest strap monitors** (such as the Polar H10 or Garmin HRM-Pro) are the gold standard. They measure the heart's electrical activity directly, giving you instantaneous, second-by-second feedback — especially valuable for patients with POTS who experience sudden postural heart rate spikes. However, they can be uncomfortable for continuous wear, especially for those with sensory sensitivities or skin reactions (MCAS). **Wrist-based smartwatches** (Apple Watch, Garmin Venu, Fitbit) offer a comfortable, lower-profile alternative with slightly delayed readings. **Smart rings** (Oura Ring) are a discreet option that tracks sleep and recovery metrics passively without a watch face. **A special note about POTS:** If you also have POTS (postural tachycardia), your heart rate may spike to 120–130 bpm simply from standing up — not from exertion. In this case, learn to distinguish postural spikes (standing up quickly, emotional startle) from true exertional load. Managing POTS through salt, fluids, and compression reduces these false alarms and makes your heart rate data more useful.[^23] #### Specialized Pacing Apps (Designed for ME/CFS) Standard fitness apps are **actively harmful** for ME/CFS patients — they are designed to push you harder, not protect you. Use apps built specifically for energy-limiting conditions: |App|Key Features|Cost| |---|---|---| |**Visible**|Pairs with armband wearable; tracks HRV and resting HR; "PacePoint" daily energy budget system; 40,000+ users; partnered with Imperial College London for research|Free (basic); subscription for full wearable features| |**CoPace**|Apple Watch integration; proprietary "Motion Filter" separates exertional HR spikes from postural spikes; automatic morning energy budget from sleep/HRV data; no data sent to servers|Free (basic); premium subscription| |**PaceME**|HRV + resting HR + weather sensitivity tracking (barometric pressure changes can worsen PEM); readiness check; CSV export for AI-assisted analysis; one-time purchase, no subscription|One-time purchase| |**WatchME**|Apple Watch + iPhone; set custom thresholds for caution/warning/critical heart rate levels; Apple Health integration|Free| All of these apps are built around the principle of **energy conservation, not athletic performance**. They are tools for safety and stability, not motivation.[^24][^25][^26][^27] A 2025 feasibility study confirmed that wearable-guided pacing in ME/CFS and Long COVID showed high adherence rates, with participants maintaining use of the intervention long-term, and the heart rate monitoring group showing measurable decreases in physiological stress metrics compared to controls.[^23] ### 2. Sleep Hygiene and Rest - Maintain consistent sleep and wake times, even if sleep quality is poor - Avoid screens and bright light for 1–2 hours before bed - If you need to rest during the day, keep rest periods in a dark, quiet room - Discuss with your doctor if sleep apnea or restless leg syndrome needs evaluation[^2] ### 3. Orthostatic Management (Managing Dizziness When Upright) - Increase fluid intake — aim for at least 2–3 liters per day - Increase salt intake (unless medically contraindicated) to expand blood volume - Use compression stockings to reduce blood pooling in the legs - Elevate the head of your bed 6–8 inches - Change positions slowly — sit before standing; stand briefly before walking - Avoid prolonged standing; use a shower chair or bath stool[^2] ### 4. Dietary Considerations While there is no established ME/CFS-specific diet, emerging microbiome research provides some dietary guidance:[^18] - **Increase dietary fiber and fermented foods** to support butyrate-producing gut bacteria (beans, lentils, oats, vegetables; yogurt, kefir, fermented vegetables) - **Be aware of tryptophan-rich foods** — tryptophan metabolism is disrupted in ME/CFS, and some patients find dietary adjustments helpful; discuss with your doctor - Keep a **food and symptom diary** — many patients have overlapping food sensitivities or MCAS that can be managed with dietary changes - **Avoid alcohol and processed foods** where possible, as these negatively affect gut microbiome diversity - Any dietary changes should be made gradually and discussed with your healthcare team ### 5. Psychological Support (Supportive — Not Curative) Cognitive Behavioral Therapy (CBT) and other counseling approaches are no longer prescribed as treatments for ME/CFS itself. However, they can play a valuable _supportive_ role in helping you navigate the grief, medical trauma, and daily challenges of living with a serious chronic illness. Seek a therapist who understands ME/CFS and does not use approaches that push exercise or dismiss your symptoms.[^1][^2] ### 6. Practical Accommodations and Aids Your doctor can and should help you obtain formal accommodations. Do not hesitate to ask:[^2] - Workplace or school adjustments (reduced hours, remote work, extended deadlines) - Documentation for disability benefits - Energy-saving mobility aids: shower chair, rollator walker, wheelchair, or mobility scooter for longer distances - Meal delivery or household support services --- ## Pharmacological (Medication) Treatments There is currently no FDA-approved medication specifically for ME/CFS. However, many medications are used **off-label** (for a purpose other than their original approval) to target the specific biological problems identified in the disease. Treatment is highly individualized — what helps one patient may not help another.[^1][^14] > **"Start Low, Go Slow"** — Patients with ME/CFS are often highly sensitive to medications, including reactions to fillers and dyes. All medications should be started at very low doses and increased gradually under close medical supervision.[^14] ### Managing Autonomic Dysfunction / Dizziness When Standing - **Pyridostigmine (Mestinon):** Improves nerve signals to blood vessels, helping veins return blood to the heart when upright. Currently being studied in the LIFT Trial at Harvard/Brigham & Women's Hospital[^12][^13] - **Midodrine:** Constricts blood vessels to raise blood pressure and reduce dizziness upon standing[^2] - **Beta-blockers (e.g., propranolol):** Slow a racing heart rate triggered by standing (POTS)[^2] - **Fludrocortisone:** A mineralocorticoid that helps the kidneys retain salt and expand blood volume[^2] ### Reducing Neuroinflammation and Immune Dysregulation - **Low-Dose Naltrexone (LDN — typically 1.5 to 4.5 mg/day):** Used at a fraction of its standard addiction-treatment dose, LDN calms overactive brain immune cells (glial cells), reduces inflammatory cytokines, and often improves brain fog and widespread pain. It is one of the most widely adopted treatments in ME/CFS clinics. A double-blind, randomized, placebo-controlled trial at the University of British Columbia (actively enrolling through 2026, funded in part by the ME Association) is the first rigorous RCT to test LDN specifically in ME/CFS and Long COVID — results are anticipated in 2026–2027.[^13][^21] - **IVIG (Intravenous Immunoglobulin):** Used in severe cases with documented immune deficiencies or strong autoantibody activity; helps modulate the immune system. Access and cost are significant barriers[^1] - **Semaglutide (Ozempic/Wegovy — GLP-1 agonist):** Currently in a 2026 clinical trial for ME/CFS. Beyond its known use for diabetes and weight management, it has powerful anti-inflammatory and metabolic effects that researchers believe may benefit ME/CFS[^6] - **Rapamycin (low-dose):** Two active clinical trials are underway — one at Simmaron Research (NCT06257420) and one at Mount Sinai's CoRE clinic. In a 2025 preliminary report from the Simmaron trial, 72.5% of participants with ME/CFS showed improvements in fatigue, PEM, and orthostatic intolerance after three months of low-dose rapamycin. Rapamycin works by inhibiting the mTOR pathway, addressing observed defects in cellular autophagy (the process by which cells clear damaged components). The Mount Sinai randomized, placebo-controlled trial is expected to conclude in late 2026.[^28] Use only under specialist supervision; this is still investigational. - **Metformin:** A well-established diabetes medication now showing promise in ME/CFS and Long COVID. A 2025 Stanford PNAS study found that metformin significantly reduced abnormal T-cell hyperproliferation in female ME/CFS patients — directly addressing the elevated oxidative stress and immune dysfunction found in this population. A clinical prophylaxis study also showed metformin reduced Long COVID incidence by 41% in treated subjects.[^29] Clinical trials in ME/CFS are being planned; discuss with your specialist. ### Supporting Cellular Energy Production - **Ubiquinol (Active CoQ10):** Supports the mitochondrial electron transport chain. Ubiquinol form has superior absorption compared to standard CoQ10 (ubiquinone)[^1] - **CoQ10 + NADH Combination:** See dedicated section below - **Oxaloacetate:** A TCA cycle intermediate that stimulates energy production and has shown dose-dependent fatigue reduction in clinical trials[^1] - **Sodium Dichloroacetate (DCA):** An off-label agent that directly targets the PDH enzyme block, helping cells produce energy aerobically instead of defaulting to anaerobic pathways[^1] - **D-Ribose:** A sugar that provides the structural building block for ATP (cellular energy currency), helping rebuild depleted energy stores[^1] - **L-Carnitine:** Helps transport fatty acids into mitochondria for energy; may be especially useful in patients with thyroid comorbidities[^1] ### Addressing Microclots and Vascular Health - **Nattokinase:** A natural enzyme from fermented soy that breaks down fibrin (clot material) and may help clear microscopic clots from capillaries. More accessible and lower-risk than pharmaceutical anticoagulants[^11] - **Triple anticoagulant therapy:** A highly experimental protocol using three anticlotting agents simultaneously. Requires specialist hematological supervision due to serious bleeding risk — not appropriate in standard primary care[^11] ### Managing Specific Symptoms - **Sleep and pain:** Low-dose amitriptyline or clonazepam may be used carefully off-label for unrefreshing sleep, sensory hyperarousal, and neuropathic pain[^2] - **Mast Cell Activation Syndrome (MCAS):** Antihistamines (cetirizine, loratadine, famotidine) and mast cell stabilizers (ketotifen) for allergic-type reactions and sensitivities[^2] - **SSRIs/SNRIs — use with caution:** ME/CFS patients have highly variable serotonin levels. Antidepressants must be prescribed thoughtfully; aggressive use can sometimes cause significant adverse reactions in this population[^2] ### Summary: Current Treatment Targets at a Glance |Target|Medications / Supplements|Status| |---|---|---| |**Autonomic / Standing Dizziness**|Pyridostigmine, Midodrine, Beta-blockers, Fludrocortisone|Off-label; widely used; LIFT Trial ongoing| |**Neuroinflammation**|Low-Dose Naltrexone (LDN)|Off-label; widely adopted; RCT in progress| |**Immune Modulation**|IVIG / Subcutaneous Ig|Severe/refractory cases only| |**mTOR / Autophagy**|Rapamycin (low-dose)|2 active clinical trials (2025–2026)| |**Oxidative Stress / Immune**|Metformin|Clinical trial planning; strong early data| |**Metabolic Research**|Semaglutide (GLP-1 agonist)|2026 Clinical Trial| |**Cellular Energy**|Ubiquinol, CoQ10+NADH, Oxaloacetate, DCA, D-Ribose, L-Carnitine|Supplement protocol; clinic-level use| |**Microclot / Vascular**|Nattokinase; Triple anticoag.|Supplement + experimental| |**Sleep / Pain**|Low-dose Amitriptyline, Clonazepam|Off-label; symptom-guided| |**MCAS**|Antihistamines, Ketotifen|Standard / off-label| --- ## CoQ10 + NADH: A Closer Look at the Evidence ### What They Are and How They Work Together **Coenzyme Q10 (CoQ10)**, also known as ubiquinone in its oxidized form and ubiquinol in its active reduced form, is a fat-soluble compound found in every cell of the body. It plays an essential role in the mitochondrial electron transport chain — the series of biochemical reactions that generate ATP (cellular energy). CoQ10 also functions as a powerful antioxidant, scavenging the harmful reactive oxygen species (ROS) that accumulate in ME/CFS due to ongoing inflammation and mitochondrial stress.[^30] **NADH** (the reduced form of nicotinamide adenine dinucleotide) is the key electron carrier that drives the electron transport chain. Without adequate NADH, the chain stalls and ATP production drops. NADH also stimulates the generation of ATP directly and supports dopamine production, which may partly explain its effect on cognitive symptoms.[^30] **Why they work better together:** NADH enhances the absorption and bioavailability of CoQ10 in the gut. Together, they have synergistic antioxidant effects that neither achieves as well alone. Both CoQ10 and NADH levels have been found to be significantly deficient in the immune cells of ME/CFS patients — and serum NADH levels correlate directly with serum CoQ10 concentrations in this population, suggesting a shared underlying deficiency.[^30] ### The Clinical Evidence The most rigorous evidence for CoQ10 + NADH in ME/CFS comes from a series of clinical trials conducted at Vall d'Hebron University Hospital in Barcelona, Spain, by Dr. Jesús Castro-Marrero and colleagues. **The landmark 2021 RCT (n=207):** A 12-week, prospective, randomized, double-blind, placebo-controlled trial enrolled 207 ME/CFS patients. Participants received either 200 mg CoQ10 + 20 mg NADH daily or a matching placebo. Key results:[^30] - **Cognitive fatigue** ("brain fog") improved significantly at both 4 weeks (p=0.005) and 8 weeks (p=0.010) in the treatment group - **Overall fatigue score (FIS-40)** showed a significant reduction at 4 weeks from baseline (p=0.022) in the treatment group - **Sleep duration** improved significantly at 4 weeks (p=0.018); habitual sleep efficiency improved at 8 weeks (p=0.038) - **Physical functioning** (SF-36 quality-of-life scale) improved significantly at both 4 and 8 weeks - **Safety:** No serious adverse events were recorded. The combination was safe and well-tolerated at the doses used This was the first RCT to test CoQ10 + NADH in a substantial number of ME/CFS patients and represented a major step forward in evidence-based treatment for this population. **The earlier pilot RCT (n=73, 2015):** An 8-week trial found that CoQ10 (200 mg/day) + NADH (20 mg/day) produced a significant reduction in overall fatigue impact score compared to placebo, alongside measurable biochemical improvements: NAD+/NADH ratio, CoQ10 levels, ATP, and the energy enzyme citrate synthase all increased significantly in treated patients' immune cells, while lipid peroxidation (a marker of oxidative damage) fell significantly.[^31] ### What the Research Shows and Its Limitations The evidence from both trials supports a real, measurable benefit — particularly for cognitive fatigue ("brain fog"), overall fatigue perception, sleep quality, and health-related quality of life. The key limitation is that improvements were statistically significant in **within-group comparisons** (treated patients improved from their baseline) but did not always reach significance in **between-group comparisons** (treated vs. placebo group), likely due to a meaningful placebo response and the relatively modest effect size. The authors also note that physical fatigue scores did not improve to the same extent as cognitive fatigue, and that longer trials in larger, more diverse populations are needed. Importantly, the trials did not assess the hallmark symptom of PEM using the gold-standard 2-day cardiopulmonary exercise test (CPET). Future trials are recommended to include this measure.[^30] ### Practical Guidance |Feature|Details| |---|---| |**Evidence-based dose**|CoQ10: 200 mg/day; NADH: 20 mg/day (from the RCTs)| |**Best form of CoQ10**|Ubiquinol (the pre-reduced, active form) has superior absorption, particularly in people over 40. Standard ubiquinone requires conversion to ubiquinol in the body — a process that may be impaired in ME/CFS| |**When to take**|With a meal containing fat (CoQ10 is fat-soluble; fat improves absorption significantly)| |**When to expect results**|Cognitive fatigue improvements were seen at 4 weeks in the RCT; allow at least 8 weeks before judging effectiveness| |**Safety**|Both are considered very safe and well-tolerated. Minor side effects (occasional nausea, epigastric discomfort) were reported in a small number of participants| |**Drug interactions**|CoQ10 may mildly reduce the effectiveness of warfarin (blood thinner) — inform your doctor if you are on anticoagulants| |**Start low**|Consistent with general ME/CFS guidance; begin at a lower dose and increase gradually if tolerated| > **This combination is not a cure and does not treat the underlying cause of ME/CFS.** It works by supporting cellular energy production and reducing oxidative stress — two of the many pathological processes involved. It is most appropriately used as part of a broader, medically supervised management plan. --- ## Significant New Research (2025–2026) The pace of ME/CFS research has accelerated dramatically, with several important findings published in the last 12 months that deepen our understanding of the disease and expand the horizon for future treatments. ### Oxidative Stress as a Shared Mechanism — and Metformin as a Candidate Treatment A landmark July 2025 study published in _PNAS_ by researchers at Stanford University identified **elevated oxidative stress** as a unifying biological signature shared by both ME/CFS and Long COVID. Studying blood lymphocytes from 27 ME/CFS and 20 Long COVID donors, the team found abnormalities in reactive oxygen species (ROS) clearance pathways, including reduced mitochondrial antioxidant enzyme levels and glutathione peroxidase-mediated lipid oxidative damage — and these patterns were strikingly sex-specific: female ME/CFS patients showed elevated total ROS correlated with T-cell hyperproliferation, while males showed pronounced mitochondrial lipid damage with normal ROS levels. Critically, metformin was shown to significantly reduce T-cell hyperproliferation specifically in female ME/CFS patients, suggesting it as a potential precision-medicine treatment for a biologically defined subgroup.[^29] ### Multi-Omics Confirmation of Innate Immune and Metabolic Dysfunction A September 2025 study in _npj Metabolic Health and Disease_ used plasma metabolomics and proteomics — both before and after exercise — to confirm an exaggerated innate immune response in ME/CFS following microbial stimulation, impaired energy production across multiple metabolic pathways, systemic inflammation linked to lipid abnormalities, gut dysbiosis, and dysregulation of tryptophan-serotonin-kynurenine pathways. Many abnormalities were worse following exercise and correlated directly with symptom severity, providing further validation of PEM's biological underpinning. The study also identified specific patient subgroups who may respond to targeted interventions including prebiotics, carnitine, and GDF15-neutralizing antibody.[^22] ### Lipid Metabolism as a New Research Direction A January 2026 multi-omics study published in the _Journal of Translational Medicine_ identified significant abnormalities in lipid metabolism in ME/CFS B-cell lines, including elevated triglycerides and saturated lipid content, and upregulation of the enzyme PTDSS1 across proteomic, transcriptomic, and lipidomic data layers. This finding points to a newly recognized intersection between lipid abnormalities and immune cell dysfunction in ME/CFS that may yield new diagnostic markers and drug targets.[^32] ### Extracellular Vesicle Biomarkers: A New Window into ME/CFS and Long COVID Two 2026 studies have identified measurable differences in **extracellular vesicles (EVs)** — tiny particles shed from cells into the bloodstream — in ME/CFS patients compared to healthy controls. A March 2026 study in _International Journal of Molecular Sciences_ found altered proteins (including hemoglobin alpha subunit and insulin-like growth factor-binding protein) and a significantly downregulated miRNA (hsa-let-7b-5p) in EVs from post-COVID ME/CFS patients, with reduced levels of this miRNA correlating with impaired physical functioning and increased fatigue, pain, and immune activation.[^33] A May 2026 study published in _Open Forum Infectious Diseases_ further found elevated EV concentrations in both ME/CFS and Long COVID groups, with increased mitochondrial membrane potential in B cell–derived EVs — pointing to immune-metabolic involvement as a shared feature of both conditions.[^34] Together, these findings open a new avenue for blood-based biomarker development that could eventually simplify diagnosis and track treatment response. ### Rapamycin Trials Show Early Promise In a 2025 preliminary report from Simmaron Research's rapamycin trial, 72.5% of 40 ME/CFS patients showed self-reported improvements in fatigue, PEM, and orthostatic intolerance after three months of low-dose rapamycin. Rapamycin is hypothesized to work by restoring the mTOR-mediated autophagy process (cellular self-cleaning) that is impaired in a subset of ME/CFS patients. A larger randomized, placebo-controlled trial is actively underway at Mount Sinai's CoRE clinic and is expected to conclude in late 2026.[^28] --- ## Prognosis: What to Expect Going Forward Receiving an ME/CFS diagnosis is challenging news, and it is important to have realistic expectations — while also knowing that your situation is **not hopeless**, and that the landscape is improving rapidly. ### The Honest Picture ME/CFS is a **chronic illness** for the majority of patients. Complete, spontaneous recovery is uncommon in adults with established disease, particularly those ill for more than two years. However, the range of outcomes is wide: - Some patients achieve **significant functional improvement** with expert management, especially when diagnosed early and when pacing is implemented consistently from the start - Many patients achieve a **stable, manageable baseline** — they do not recover fully, but they learn to live well within their limits - A smaller proportion experience severe, progressive decline, particularly if PEM is repeatedly triggered by overexertion - Children and adolescents generally have better recovery rates than adults[^2] - Research suggests that microbiome disruptions may become more entrenched with longer disease duration, reinforcing the importance of early diagnosis and management[^18] ### Factors That Influence Outcomes - **Early diagnosis and pacing:** The most important modifiable factor. Patients who rest and pace effectively from the start avoid the cumulative damage of repeated PEM crashes[^2] - **Severity at diagnosis:** Milder presentations tend to have more favorable trajectories - **Identification and treatment of comorbidities:** Treating orthostatic intolerance, MCAS, or sleep disorders can significantly reduce overall symptom burden[^2] - **Avoiding harmful treatments:** Avoiding forced exercise programs is critical to preventing permanent worsening[^10] ### Reasons for Genuine Hope The period from 2020–2026 has seen more progress in ME/CFS research than the preceding three decades combined, largely driven by the overlap with Long COVID and a surge in research funding:[^1][^6] - The **TRPM3 ion channel** discovery provides the first universally confirmed structural target for future drug development[^4] - The **LIFT Trial** (LDN + Pyridostigmine, Harvard/Brigham & Women's) is on track to establish the first proven combination pharmacotherapy protocol[^12] - **Two rapamycin trials** are producing early encouraging results, with a randomized controlled trial at Mount Sinai expected to report in late 2026[^28] - **Metformin** has shown significant effects on ME/CFS immune dysfunction in a 2025 Stanford study, with clinical trials being planned[^29] - A landmark **2026 Semaglutide trial** is testing a promising new class of metabolic anti-inflammatory agents[^6] - **DecodeME** — the world's largest ME/CFS genetic study — has identified eight specific genetic signals linked to immune and nervous system function, opening entirely new research directions for biomarker and drug development[^20] - **BioMapAI** demonstrated 90% accuracy in identifying ME/CFS from stool, blood, and routine labs — bringing objective diagnostic testing closer to clinical reality[^18] - The **EpiSwitch® blood test** (chromosome conformation-based) achieved 96% accuracy in research settings — potentially offering a future diagnostic tool[^19] - **Extracellular vesicle research** (2026) has identified new blood-based biomarker candidates that may transform diagnosis and monitoring[^33][^34] - An LDN randomized controlled trial is actively underway and will provide the most rigorous evidence yet for this widely-used treatment[^21] - Global clinical guidelines have been rewritten to be patient-centered and biologically grounded — better-informed doctors mean better care[^2][^8][^9] - **ME/CFS has its own ICD-10-CM diagnostic code (G93.32)**, improving access to appropriate billing, documentation, and disability recognition[^16] --- > **A Message to You** > > Your illness is real. It is biological. It is not "all in your head," and it is not caused by inactivity or negative thinking. What you are experiencing has a measurable basis in your immune system, your mitochondria, your gut, your blood vessels, and your DNA. You deserve compassionate, evidence-based care. Advocate for yourself, connect with patient communities, and work with your healthcare team to find your personal management plan. Science is catching up — and the momentum is real. --- ## Key References [^1]: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). PMC, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12801797/ [^2]: Latest NICE ME/CFS Guidance Summary (2026). https://iatrox.com/guidelines/me-cfs [^3]: U.S. ME/CFS Clinician Coalition. https://mecfscliniciancoalition.org [^4]: New research confirms people with ME/CFS have a consistent faulty cellular structure. Griffith University, January 2026. https://news.griffith.edu.au/2026/01/13/new-research-confirms-people-with-me-cfs-have-a-consistent-faulty-cellular-structure/ [^5]: Assessment and Incidence Determination of ME/CFS Following a SARS-CoV-2 Infection. MDPI, 2026. https://www.mdpi.com/1648-9144/62/3/480 [^6]: New Catalyst Awards to Accelerate ME/CFS and Long Covid Breakthroughs. Solve ME/CFS Initiative, February 2026. https://solvecfs.org/february-2026-catalyst-awards/ [^7]: Bateman Horne Center Clinical Care Guide, First Edition 2025. https://batemanhornecenter.org [^8]: NICE Guideline NG206: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management. https://www.nice.org.uk/guidance/ng206 [^9]: National Advisory on ME releases Best Practice Guidance. ANZMES, 2026. https://anzmes.org.nz [^10]: Why Graded Exercise Therapy Is Harmful in ME/CFS: The Evidence and the Controversy. RTHM, 2026. https://www.rthm.com/resources/blogs/graded-exercise-controversy-me-cfs [^11]: Microclots in Post-COVID Condition: Clinical and Biomarker Response to Triple Antithrombotic Therapy. Preprints.org, 2026. https://www.preprints.org/manuscript/202602.0988/v1/download [^12]: The Life Improvement Trial (LIFT). Open Medicine Foundation. https://clinicaltrials.gov/study/NCT06366724 [^13]: Low-dose Naltrexone & Mestinon RCT in ME/CFS and Long COVID. ME/CFS Research Foundation Conference, 2025. https://events.mecfs-research.org [^14]: ME/CFS Treatment Recommendations. U.S. ME/CFS Clinician Coalition / Bateman Horne Center, February 2021. https://batemanhornecenter.org/wp-content/uploads/filebase/Treatment-Recs-MECFS-Clinician-Coalition-V1-Feb.-2021.pdf [^15]: Reframing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Biological Basis of Disease and Recommendations for Supporting Patients. MDPI Healthcare, 2026. https://www.mdpi.com/2227-9032/13/15/1917 [^16]: ICD-10-CM Code G93.32 for ME/CFS. CDC. https://www.cdc.gov/me-cfs/hcp/diagnosis/index.html [^17]: Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. NIH/NINDS — Walitt et al., Nature Communications, 2024. https://doi.org/10.1038/s41467-024-45107-3 [^18]: BioMapAI: Artificial Intelligence Multi-Omics Modeling of ME/CFS. Jackson Laboratory / Duke University — Xiong et al., Nature Medicine, July 2025. https://www.jax.org/news-and-insights/2025/july/gut-microbiome-may-predict-invisible-chronic-fatigue-syndrome-and-long-covid [^19]: Development and validation of blood-based diagnostic biomarkers for ME/CFS using EpiSwitch®. Hunter et al., Journal of Translational Medicine, 2025. https://meassociation.org.uk/2025/10/blood-test-can-detect-me-cfs-uea-researchers-claim/ [^20]: Initial findings from the DecodeME genome-wide association study of ME/CFS. DecodeME Collaboration, University of Edinburgh, August 2025 (preprint). https://www.medrxiv.org/content/10.1101/2025.08.06.25333109v1 [^21]: A Double-Blind Randomized Trial of Low-Dose Naltrexone for ME/CFS and Long COVID. University of British Columbia / ME Association, initiated March 2025. https://meassociation.org.uk/2025/07/update-low-dose-naltrexone-ldn-clinical-trial-progress-report-april-june-2025/ [^22]: Heightened innate immunity may trigger chronic inflammation, fatigue and post-exertional malaise in ME/CFS. npj Metabolic Health and Disease, September 2025. https://www.nature.com/articles/s44324-025-00079-w [^23]: Heart Rate Monitoring for Pacing: Using Wearables to Manage Energy. RTHM Medical Team, March 2026. https://www.rthm.com/resources/blogs/hr-monitoring-chronic-illness; also: Clague-Baker N et al. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue: Biomedicine, Health & Behavior, 2025. https://www.tandfonline.com/doi/full/10.1080/21641846.2025.2565103 [^24]: Visible App. ME Association review, April 2024. https://meassociation.org.uk/2024/04/visible-the-pacing-app-for-people-with-me-cfs-and-long-covid/ [^25]: CoPace: Pacing & Energy Limit App. App Store. https://apps.apple.com/au/app/copace-pacing-energy-limit/id6757660550 [^26]: PaceME: Pacing & Energy App. App Store. https://apps.apple.com/gb/app/paceme-pacing-energy/id6760505520 [^27]: WatchME: ME/CFS Pacing. App Store. https://apps.apple.com/us/app/watchme/id1583153009 [^28]: Clinical Trials Are Testing Cancer Drug Rapamycin for Long COVID and ME. Cancer Health / The Sick Times, August 2025. https://www.cancerhealth.com/article/clinical-trials-testing-cancer-drug-rapamycin-long-covid; NCT06257420. https://clinicaltrials.gov/study/NCT06257420 [^29]: Oxidative stress is a shared characteristic of ME/CFS and Long COVID. Davis MM et al., PNAS, July 2025. https://www.pnas.org/doi/full/10.1073/pnas.2426564122 [^30]: Castro-Marrero J et al. Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with ME/CFS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, 2021;13(8):2658. https://www.mdpi.com/2072-6643/13/8/2658; PMC: https://ncbi.nlm.nih.gov/pmc/articles/PMC8399248/ [^31]: Castro-Marrero J et al. Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in Chronic Fatigue Syndrome? Antioxidants & Redox Signaling, 2015;22(8):679–685. https://pubmed.ncbi.nlm.nih.gov/25386668/ [^32]: Multi-omics identifies lipid accumulation in ME/CFS cell lines: a case-control study. Journal of Translational Medicine, January 2026. https://link.springer.com/article/10.1186/s12967-025-07620-x [^33]: Seifert M et al. Extracellular Vesicle Protein and MiRNA Signatures as Biomarkers for Post-Infectious ME/CFS Patients. International Journal of Molecular Sciences, 2026;27(5):2314. https://www.mdpi.com/1422-0067/27/5/2314 [^34]: Ikeda G et al. Plasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell-Associated Mitochondrial Membrane Potential Alterations in Long COVID and ME/CFS. Open Forum Infectious Diseases, May 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13166156/ --- _This handout is for educational purposes only. It does not replace individualized medical advice. Please consult your healthcare provider for diagnosis and treatment decisions. Information is current as of May 2026._